News
MinervaX announces completion of 47.4 mEUR financing
MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials On the back of highly promising Phase Ib...
MinervaX announces investment of 4.4 mEUR
MinervaX announces award of 4.4 million euro in investment from Novo Holding's repair impact fund and Sunstone Life Science Ventures for further clinical development of the...
MinervaX announces results from Phase I clinical trial
MinervaX announces positive results from Phase I trial in 240 healthy adult women with its innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections...
Innovation Foundation Grant
MinervaX announces that the company has been awarded a grant worth DKK 4.1 million (EUR 0.6 million) from the Danish Innovation Foundation, under the Innobooster Programme, for...
Primary Endpoint Data from Phase I Part B
MinervaX announces that it today data have been received from the primary 3-month time point clinical endpoint of the Phase I Part B. The data supports dose-selection made based...
Completion of enrollment of Phase I Part B
MinervaX announces that it today has enrolled and dosed the last of 240 subjects in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN.
Equity Financing
MinervaX announces that the company has raised DKK 16 million (EUR 2.2 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an...
Innovation Foundation Grant
MinervaX announces that the company has been awarded a grant worth DKK 4.5 million (EUR 0.6 million) from the Danish Innovation Foundation, under the Innobooster Programme, for...
Initiation of Phase I Part B
MinervaX announces that it today has dosed the first subject in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN, due to enrol 240 healthy...
